Castro Bárbara Neto, Costa Catarina, Martins Daniel, Amado Andreia, Santos Mariana, Graça Susana, Tavares Amélia, Ferreira António, Viveiros Fernando, Vale Sílvio, Oliveira Manuel
General Surgery Department, Centro Hospitalar Vila Nova de Gaia/Espinho, Vila Nova de Gaia, Portugal.
Porto Biomed J. 2024 Mar 8;9(2):247. doi: 10.1097/j.pbj.0000000000000247. eCollection 2024 Mar-Apr.
Solid tumors are a common cause of secondary thrombocytosis, which has been identified as a prognostic factor in various cancers. However, the impact of thrombocytosis on the prognosis of gastric cancer is not yet well defined. The aim of this study was to assess the prevalence and prognostic value of thrombocytosis in patients with gastric cancer.
This was a retrospective study of patients with gastric carcinoma treated surgically, with curative intent, in our hospital, Centro Hospitalar Vila Nova de Gaia/Espinho, between January 2009 and December 2019. Clinical files were consulted and clinicopathological characteristics were analyzed.
In the present sample (n = 352), the prevalence of pretreatment thrombocytosis was 16.5%. Thrombocytosis was associated with more advanced T stage, greater number of metastatic nodes, and more frequent lymphatic and venous permeation. The presence of thrombocytosis had a negative impact on disease-free survival (hazard ratio [HR] 3.54, 95% confidence interval [CI] 2.35-5.33, < .001) and overall survival (HR 4.45, 95% CI 2.95-6.71, < .001).
The presence of pretreatment thrombocytosis had a negative impact on overall survival and disease-free survival and thus could be used as an independent prognostic factor.
实体瘤是继发性血小板增多症的常见原因，继发性血小板增多症已被确定为多种癌症的预后因素。然而，血小板增多症对胃癌预后的影响尚未明确界定。本研究的目的是评估胃癌患者血小板增多症的患病率及其预后价值。
这是一项对2009年1月至2019年12月期间在我院（盖亚新城/埃斯皮尼奥中心医院）接受手术治疗且有治愈意图的胃癌患者进行的回顾性研究。查阅临床档案并分析临床病理特征。
在本样本（n = 352）中，术前血小板增多症的患病率为16.5%。血小板增多症与更晚期的T分期、更多的转移淋巴结数量以及更频繁的淋巴和静脉浸润相关。血小板增多症的存在对无病生存期（风险比[HR] 3.54，95%置信区间[CI] 2.35 - 5.33，P <.001）和总生存期（HR 4.45，95% CI 2.95 - 6.71，P <.001）有负面影响。
术前血小板增多症的存在对总生存期和无病生存期有负面影响，因此可作为独立的预后因素。
